Tolerogenic dendritic cells for reprogramming of lymphocyte responses in autoimmune diseases

Publication date: Available online 30 July 2016
Source:Autoimmunity Reviews
Author(s): Paulina García-González, Gabriela Ubilla-Olguín, Diego Catalán, Katina Schinnerling, Juan Carlos Aguillón
Dendritic cells (DCs) control immune responses by driving potent inflammatory actions against external and internal threats while generating tolerance to self and harmless components. This duality and their potential to reprogram immune responses in an antigen-specific fashion have made them an interesting target for immunotherapeutic strategies to control autoimmune diseases. Several protocols have been described for in vitro generation of tolerogenic DCs (tolDCs) capable of modulating adaptive immune responses and restoring tolerance through different mechanisms that involve anergy, generation of regulatory lymphocyte populations, or deletion of potentially harmful inflammatory T cell subsets. Recently, the capacity of tolDCs to induce interleukin (IL-10)-secreting regulatory B cells has been demonstrated. In vitro assays and rodent models of autoimmune diseases provide insights to the molecular regulators and pathways enabling tolDCs to control immune responses. Here we review mechanisms through which tolDCs modulate adaptive immune responses, particularly focusing on their suitability for reprograming autoreactive CD4+ effector T cells. Furthermore, we discuss recent findings establishing that tolDCs also modulate B cell populations and also examine on clinical trials applying tolDCs to patients with autoimmune diseases.



from #ENT via xlomafota13 on Inoreader http://ift.tt/2anAXn7
via IFTTT